At week 14 in the GO-FORWARD trial , total cholesterol ( TC ) , high-density lipoprotein ( HDL ) and low-density lipoprotein ( LDL ) increased in golimumab + MTX patients versus MTX-only patients ( 16.00 vs 2.00 ( p < 0.001 ) ; 3.00 vs 0.00 ( p < 0.05 ) ; 8.00 vs 4.00 ( p < 0.001 ) ; respectively ) ; favourable changes in LDL subfractions were only observed in golimumab-treated patients .
